Director Georges Gemayel of Supernus Pharmaceuticals Inc (SUPN, Financial) sold 13,886 shares of the company on September 13, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 13,315 shares of the company.
Supernus Pharmaceuticals Inc (SUPN, Financial) specializes in the development and commercialization of products for the treatment of central nervous system diseases. The company's portfolio includes treatments for epilepsy, migraine, and attention deficit hyperactivity disorder among others.
On the day of the transaction, shares of Supernus Pharmaceuticals Inc (SUPN, Financial) were priced at $31.33. This pricing gives the company a market cap of approximately $1.75 billion. The price-earnings ratio of the company stands at 356.40, significantly above both the industry median of 22.81 and the company's historical median.
The stock is considered to be Fairly Valued with a price-to-GF Value ratio of 0.97, based on a GF Value of $32.31. The GF Value is calculated considering historical trading multiples, an adjustment factor based on past returns and growth, and future business performance estimates from analysts.
Over the past year, there have been no insider buys at Supernus Pharmaceuticals Inc (SUPN, Financial), but there have been 11 insider sells, indicating a trend of insider sales. The insider transaction history and the current valuation metrics provide a comprehensive view of the company's recent financial maneuvers and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
